8 results
Primary ObjectiveTo evaluate the effect of a single 84-mg dose of intranasal esketamine compared to placebo, on next day driving performance and repeated administration of 84 mg intranasal esketamine on same-day driving performance as assessed by…
This explorative study aims to investigate the added value of a 18F-PSMA PET to mpMRI in the detection of local prostate cancer lesions.
To evaluate the effect of intranasal esketamine 84 mg on cognition, and duration of cognitive effects (if present), as assessed using a computerized test battery (Cogstate®).
Therefore, this feasibility study will evaluate whether the 18F-PSMA PET/CT is capable of MTC lesion detection. Moreover, we will compare its ability to detect MTC lesions with a routinely used PET scan, the 18F-FDG PET. By exploring new tracers in…
Phase 1:The primary objective of this trial is to investigate whether oral esketamine is non-inferior to ECT after eight weeks of individually optimized treatment, in participants with NTRD.Phase 2:To compare the efficacy of maintenance oral…
Objective: Primary objective: To determine pharmacokinetic profiles of an esketamine oral thin film with 50 or 100 mg esketamine; Secondary objective: (1) To determine the pharmacodynamic profile of an esketamine oral thin film containing 50 or 100…
The primary objective is to investigate whether pharmacological conditioning with S(+)-ketamine compared to pharmacological conditioning with placebo medication reduces pain sensitivity in patients with FMS.
To investigate whether oral esketamine is non-inferior to ECT in achieving treatment response on depression severity in NTRD.